HDAC9 and Miyoshi myopathy: Three inhibitors of all HDAC classes (pan-HDAC inhibitors)—vorinostat, belinostat, romidepsin—received FDA approval for T-cell lymphomas during the 2006–2014 period, but each failed to demonstrate any clear benefit as a single agent in MM.